CMA Phase 1 Deadline Falls Today for AkzoNobel and Axalta Coatings Merger
The Competition and Markets Authority (CMA) reached its statutory Phase 1 decision deadline on 11 November 2026 for the anticipated merger between Akzo Nobel N.V. and Axalta Coating Systems Ltd, two major participants in the global industrial coatings and paint sector. The inquiry was formally launched on 16 September 2026, following an invitation-to-comment period that ran from 16 April to 1 May 2026. The CMA is investigating the deal under its merger control powers, with the case classified under the chemicals market sector. The statutory timetable confirms today as the deadline for the Phase 1 decision, though the CMA retains the ability to extend that deadline in limited circumstances. At Phase 1, the CMA assesses whether the transaction gives rise to a realistic prospect of a substantial lessening of competition in the UK. If concerns are identified, the case proceeds to a more intensive Phase 2 investigation. The chemicals and coatings sector is one where product market definition and geographic market analysis are particularly important, as industrial coatings supply chains are global but competition assessments are often conducted on a national or regional basis. The CMA's Phase 1 decision was announced today: it found that the merger may be expected to result in a substantial lessening of competition, and the deal will be referred for an in-depth Phase 2 investigation unless AkzoNobel and Axalta offer an acceptable undertaking.
Why this matters
The AkzoNobel and Axalta combination would bring together two significant players in the global coatings market, and the CMA's scrutiny reflects the broader pattern of UK merger control remaining active and independent post-Brexit. The CMA's Phase 1 decision, announced today, found that the merger may be expected to result in a substantial lessening of competition. That finding means a Phase 2 referral now looms unless an acceptable undertaking is offered, which would significantly complicate deal completion timelines. The case illustrates how the CMA continues to review cross-border industrial mergers affecting UK supply chains, even where the combining parties are headquartered outside the UK.
On the Ground
Competition law practices at firms advising either party will be intensely focused on responding to the CMA's Phase 1 decision announced today, which found a realistic prospect of a substantial lessening of competition and will refer the merger to Phase 2 unless the parties offer an acceptable undertaking. If a Phase 2 referral follows, the matter will generate substantial regulatory work including market questionnaires, economic analysis, and possible remedy design. M&A practices will be on standby to advise on deal conditionality and timetable. A trainee on this matter would assist with drafting regulatory notification documents, maintaining a CP (conditions precedent) checklist tracking CMA milestones, and indexing due diligence materials related to the UK competitive overlap.
Interview prep
Question you might get
“What happens if the CMA refers the AkzoNobel and Axalta merger to a Phase 2 investigation, and what options would the parties have?”
Sign up free to see the full answer
A model answer you can lift into an interview — how to frame this story for a partner.
Sign up freeMy notes
saved